LILRB4 represents a promising target for immunotherapy by dual targeting tumor cells and myeloid-derived suppressive cells in multiple myeloma.
Gong L, Sun H, Liu L, Sun X, Fang T, Yu Z, Sui W, Xu J, Wang T, Feng F, Lei L, Rui W, Liu Y, Zhao X, An G, Lin X, Qiu L, Hao M.
Gong L, et al.
Haematologica. 2024 May 30. doi: 10.3324/haematol.2024.285099. Online ahead of print.
Haematologica. 2024.
PMID: 38813706
Free article.